BioCentury
ARTICLE | Clinical News

Adolor's ADL 2-1294 fails Phase II

December 21, 2001 8:00 AM UTC

ADLR said data from a double-blind, placebo-controlled Phase II trial did not show a statistically significant difference between its ADL 2-1294 loperamide topical dermal agent and placebo in patients...